Please enable JS

PRESS RELEASE

CRISPR Therapeutics Congratulates Scientific Founder Dr. Emmanuelle Charpentier on Addition to TIME Magazine’s 100 Most Influential People and Award of Louis Jeantet Prize for Medicine

BASEL, Switzerland and CAMBRIDGE, Massachusetts – April 22, 2015 – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines for serious human diseases, congratulates its scientific founder, Dr. Emmanuelle Charpentier, for being named to TIME Magazine’s TIME 100 Most Influential People in the World alongside fellow CRISPR/Cas9 discoverer, Dr. Jennifer Doudna. In addition, Dr. Emmanuelle was awarded the Louis Jeantet Prize for Medicine, considered the most prestigious European award for researchers in the life sciences, for her discovery of the CRISPR/Cas9 gene editing tool. She will receive the award in a ceremony in Geneva, Switzerland, on April 22, 2015.

“Being named to TIME Magazine’s TIME 100 and awarded the Louis Jeantet Prize for Medicine is a testament to Dr. Charpentier’s revolutionary work with CRISPR/Cas9, which has significant potential to cure serious human diseases,” said Dr. Rodger Novak, Chief Executive Officer of CRISPR Therapeutics. “We are proud of her accomplishments and the continued acknowledgement of her work and the CRISPR/Cas9 technology for the quantum leap in medicine we believe it to be.”

Dr. Charpentier has received numerous additional awards for her research, including in 2014 the Alexander von Humboldt Professorship, the Dr Paul Janssen Award, the Grand-Prix Jean-Pierre Lecocq (French Academy of Sciences), the Göran Gustafsson Prize (Royal Swedish Academy of Sciences) and in 2015 the Breakthrough Prize in Life Sciences. She was also selected as one of the American Foreign Policy magazine’s 100 Leading Global Thinkers for 2014.

About CRISPR Therapeutics
CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR/Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human diseases. We were launched out of the Basel-based Versant Ventures offices in 2013 and have undertaken translational development programs in several important disease areas with our collaborators in Europe and the US. Our vision is to cure serious human diseases at the molecular level using CRISPR/Cas9. www.crisprtx.com.

MEDIA CONTACTS:
MacDougall Biomedical Communications
Michelle Avery in US – mavery@macbiocom.com +1 (781) 235-3060
Anca Alexandru in Europe – aalexandru@macbiocom.com +49 (89) 2424-3494